Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 51

Results For "Mpower"

551 News Found

Dr. Reddy’s impresses on sustainability and gender equality again
Sustainability | February 03, 2022

Dr. Reddy’s impresses on sustainability and gender equality again

Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row


Budget 22-23: Healthcare sector applauds focus on mental health
News | February 01, 2022

Budget 22-23: Healthcare sector applauds focus on mental health

A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook


HealthPlix is in NASSCOM’s `League of 10’ companies 2021
Startup | January 28, 2022

HealthPlix is in NASSCOM’s `League of 10’ companies 2021

The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year


Sanofi signs as first partner of Protas
Biotech | January 25, 2022

Sanofi signs as first partner of Protas

The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases


CliniSys creates world’s largest diagnostics and lab informatics with recent acquisitions
News | January 19, 2022

CliniSys creates world’s largest diagnostics and lab informatics with recent acquisitions

CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe


Healthcare for seniors an opportunity for service providers
Public Health | January 19, 2022

Healthcare for seniors an opportunity for service providers

Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID
Public Health | January 03, 2022

Snapdeal to promote Ayushman Bharat Digital Mission’s Heath ID

The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records